Ross H M, Smelstoys J A, Davis G J, Kapatkin A S, Del Piero F, Reineke E, Wang H, Zhu T C, Busch T M, Yodh A G, Hahn S M
Department of Surgery, Division of Colon and Rectal Surgery, University of Pennsylvania, School of Medicine, Philadelphia, Pennsylvania 19096, USA.
J Surg Res. 2006 Oct;135(2):323-30. doi: 10.1016/j.jss.2006.01.020. Epub 2006 May 2.
Local recurrence of rectal cancer remains a significant clinical problem despite multi-modality therapy. Photodynamic Therapy (PDT) is a cancer treatment which generates tumor kill through the production of singlet oxygen in cells containing a photosensitizing drug when exposed to laser light of a specific wavelength. PDT is a promising modality for prevention of local recurrence of rectal cancer for several reasons: tumor cells may selectively retain photosensitizer at higher levels than normal tissues, the pelvis after mesorectal excision is a fixed space amenable to intra-operative illumination, and PDT can generate toxicity in tissues up to 1 cm thick. This study evaluated the safety, tissue penetration of 730 nm light, normal tissue toxicity and surgical outcome in a dog model of rectal resection after motexafin lutetium-mediated photodynamic therapy.
Ten mixed breed dogs were used. Eight dogs underwent proctectomy and low rectal end to end stapled anastomosis. Six dogs received the photosensitizing agent motexafin lutetium (MLu, Pharmacyclics, Inc., Sunnyvale, CA) of 2 mg/kg preoperatively and underwent subsequent pelvic illumination of the transected distal rectum of 730 nm light with light doses ranging from 0.5 J/cm(2) to 10 J/cm(2) three hours after drug delivery. Two dogs received light, but no drug, and underwent proctectomy and low-rectal stapled anastomosis. Two dogs underwent midline laparotomy and pelvic illumination. Light penetration in tissues was determined for small bowel, rectum, pelvic sidewall, and skin. Clinical outcomes were recorded. Animals were sacrificed at 14 days and histological evaluation was performed.
All dogs recovered uneventfully. No dog suffered an anastomotic leak. Severe tissue toxicity was not seen. Histological findings at necropsy revealed mild enteritis in all dogs. The excitation light penetration depths were 0.46 +/- 0.18, 0.46 +/- 0.15, and 0.69 +/- 0.39 cm, respectively, for rectum, small bowel, and peritoneum in dogs that had received MLu. For control dogs without photosensitizer MLu, the optical penetration depths were longer: 0.92 +/- 0.63, 0.67 +/- 0.10, and 1.1 +/- 0.80 cm for rectum, small bowel, and peritoneum, respectively.
Low rectal stapled anastomosis is safe when performed with MLu-mediated pelvic PDT in a dog model. Significant tissue penetration of 730 nm light into the rectum and pelvic sidewall was revealed without generation of significant toxicity or histological sequelae. Penetration depths of 730 nm light in pelvic tissue suggest that microscopic residual disease of less than 5 mm are likely to be treated adequately with MLu-mediated PDT. This approach merits further investigation as an adjuvant to total mesorectal excision and chemoradiation for rectal cancer.
尽管采用了多模式治疗,但直肠癌的局部复发仍然是一个重大的临床问题。光动力疗法(PDT)是一种癌症治疗方法,当暴露于特定波长的激光时,它会通过在含有光敏药物的细胞中产生单线态氧来杀死肿瘤。PDT有望用于预防直肠癌的局部复发,原因如下:肿瘤细胞可能比正常组织选择性地保留更高水平的光敏剂,直肠系膜切除术后的骨盆是一个固定空间,适合术中照明,并且PDT可以在厚度达1厘米的组织中产生毒性。本研究评估了在莫特沙芬镥介导的光动力疗法后直肠切除犬模型中730纳米光的安全性、组织穿透性、正常组织毒性和手术结果。
使用了10只杂种犬。8只犬接受了直肠切除术和低位直肠端端吻合术。6只犬术前接受了2毫克/千克的光敏剂莫特沙芬镥(MLu,Pharmacyclics公司,加利福尼亚州桑尼维尔),给药3小时后,对横断的远端直肠进行730纳米光的盆腔照射,光剂量范围为0.5焦/平方厘米至10焦/平方厘米。2只犬接受了光照,但未用药,然后进行了直肠切除术和低位直肠吻合术。2只犬进行了中线剖腹术和盆腔照射。测定了小肠、直肠、盆腔侧壁和皮肤的光穿透情况。记录临床结果。动物在14天时处死并进行组织学评估。
所有犬均顺利恢复。没有犬发生吻合口漏。未观察到严重的组织毒性。尸检时的组织学发现显示所有犬均有轻度肠炎。接受MLu的犬的直肠、小肠和腹膜的激发光穿透深度分别为0.46±0.18厘米、0.46±0.15厘米和0.69±0.39厘米。对于没有光敏剂MLu的对照犬,光穿透深度更长:直肠、小肠和腹膜的光穿透深度分别为0.92±0.63厘米、0.67±0.10厘米和1.1±0.80厘米。
在犬模型中,采用MLu介导的盆腔PDT进行低位直肠吻合术是安全的。730纳米光可显著穿透直肠和盆腔侧壁组织,且不会产生明显毒性或组织学后遗症。730纳米光在盆腔组织中的穿透深度表明,小于5毫米的微小残留病变可能通过MLu介导的PDT得到充分治疗。作为直肠癌全直肠系膜切除和放化疗的辅助手段,这种方法值得进一步研究。